The FDA grants 510(k) clearance for Becton, Dickinson's (NYSE:BDX) PleurX catheter system for use in specific non-malignant recurrent pleural effusions etiologies, including congestive heart failure. A pleural effusion is a collection of fluid that accumulates in the pleural cavity that surrounds the lungs that causes the person to be short of breath.
The PleurX system allows the patient to drain pleural fluid in a home setting. It was initially approved in 1997 for managing malignant and recurrent pleural effusions.
Now read: DGI For The DIY: 2016 Portfolio Review »